Then and Now: This Month in Endocrine History Submitted by Evan Graber, DO In 1958, in a Letter to the…
More Articles
Dear PES membership, In my final month as your president, I wish to relate to you my sincere gratitude to all of you for allowing me to serve in this…
Shreshtha Banga, MD My journey began in India, where I grew up as the child of two Pediatricians, naturally gravitating towards Pediatrics myself. I pursued my dream by completing an…
Historical Tidbit: Sir Victor Alexander Haden Horsley (1857 to 1916) and Myxoedema Submitted by Alan D. Rogol, MD, Ph.D. Horsley, a surgeon, professor and superintendent of the Brown Institution in…
Spring has arrived and much is stirring at PES. Finishing touches of our Strategic Plan for the next 5 years is near completion, thanks to President-Elect Mark Palmert. Preparations for…
In March 2023, the FDA extended the approval of Evinacumab (EVKEEZA©) to children 5-11 years with familial homozygous hypercholesteremia. Evinacumab had been previously approved for 12 and older (2021), as…
Edward Schäfer (aka Sharpey-Schäfer) June 2, 1850 to March 29, 1935 and Endocrine Physiology Submitted by Alan D. Rogol, MD, Ph.D. Edward Schäfer took on the name of his mentor,…
Lexi Dias, DO My name is Lexi Dias and I am a third year pediatric endocrine fellow at Yale. My training has taken me to many interesting places, but I…
The snow is falling, clinics are cancelled, staff is scrambling to call patients for reappointments, and coordinators are rebooking research participants due to the storm. . .but the snow is…
From: Novo Nordisk (mail@communications.novonordisk.com) Due to higher than anticipated demand, Novo Nordisk will be unable to provide the Sogroya 15 mg pen from Mid-February through May 2024. However, there is…
US FDA-approval of VAMOROLONE for Duchenne Muscular Dystrophy (DMD)*-a novel alternative steroid with unique properties. New Drugs and Therapeutics On October 26, 2023, the US Food and Drug Administration…